CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 106 enrolled
Drug / intervention
methylphenidate or placebodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00844090
NCT00844090N/ACompleted
CompareCT.gov

The Role of Apathy in Glycemic Control

US Department of Veterans Affairs·interventional·Posted Feb 13, 2009·Updated Apr 21, 2014

In Brief

A clinical study evaluating methylphenidate or placebo for Apathy and Diabetes. Completed, enrolled 106 participants across 1 site.

Detailed Summary

In spite of several new medications and insulins for the control of blood sugars in patients with diabetes, a large number of patients do not have good control. This likely due to inability to carry out regular activities and self-care behaviors such as taking meds regularly, keeping a good diet, exercise etc. This inability to carry out self care lifestyle changes may be due to a condition called apathy. Apathy is a lack of motivation and persistence. In this study we will attempt to treat apathy with a medication called methylphenidate for 6 months and see if blood sugar/diabetes control improves.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsApathy, Diabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 13, 2009
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.4 years ago

Interventions

methylphenidate or placebodrug

treat apathy to improve diabetes self care behaviors thereby improving glycemic control